Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Maribavir showed no clear difference in adverse events compared with ganciclovir (moderate certainty).
Antiviral prophylaxis showed no clear difference in graft loss compared with placebo or no treatment (moderate certainty).
Antiviral prophylaxis showed no clear difference in acute rejection compared with placebo or no treatment (high certainty).
Antiviral prophylaxis showed no clear difference in leucopenia compared with placebo or no treatment (moderate certainty).
Antiviral prophylaxis showed no clear difference in kidney dysfunction compared with placebo or no treatment (low certainty).
Ganciclovir leads to lower CMV disease compared with aciclovir (high certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Renin‐angiotensin system inhibition may leads to lower > 50% increase in SCr compared with other supportive care treatment (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Tonsillectomy plus standard care may leads to higher remission of proteinuria compared with standard care (low certainty).
Tonsillectomy plus standard care may leads to higher remission of haematuria (microscopic) compared with standard care (low certainty).
It is very uncertain whether tonsillectomy plus standard care changes relapse of haematuria (macroscopic) compared with standard care (very low certainty).
Renin‐angiotensin system inhibition showed no clear difference in kidney failure or doubling of SCr compared with placebo or no treatment (low certainty).